ANIK

Business Context and Reporting Period

Company: Anika Therapeutics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2003
Business Overview: Anika develops, manufactures, and commercializes therapeutic products based on hyaluronic acid (HA) for bone, cartilage, and soft tissue protection. Key products include ORTHOVISC (osteoarthritis), HYVISC (equine osteoarthritis), and ophthalmic viscoelastic products (AMVISC, CoEase, etc.).

Key Financial Metrics (Year Ended Dec 31, 2003)

Debt & Liquidity: The company reported no long-term debt. Liquidity is supported by cash reserves and a significant milestone payment received in February 2004 (post-period).

Material Changes vs. Prior Period

• Profitability Turnaround: The company returned to profitability in 2003 with net income of $0.8 million, reversing a $3.0 million net loss in 2002.
• Revenue Growth: Total revenue increased 17% to $15.4 million, driven by a 33% increase in ORTHOVISC sales and a 91% increase in HYVISC sales.
• Margin Expansion: Gross margin improved from 39% to 48% due to a higher margin product mix and manufacturing efficiencies.
• Expense Reduction: Research and Development (R&D) expenses decreased 34% to $2.6 million, primarily due to the completion of the pivotal ORTHOVISC clinical trial. Selling, General, and Administrative (SG&A) expenses decreased 5% to $4.2 million.
• Customer Concentration: Bausch & Lomb accounted for 51% of product revenue in 2003, down from 59% in 2002.

Guidance, Outlook, and Risks

Strategic Developments:

• ORTHOVISC U.S. Launch: Received FDA approval in February 2004 and launched in the U.S. on March 1, 2004, under a 10-year licensing agreement with Ortho Biotech Products, L.P. (Johnson & Johnson family).
• Financial Impact of Agreement: Received a $2.0 million upfront payment in Dec 2003 and a $20.0 million milestone payment in Feb 2004. These amounts will be recognized ratably over the 10-year term, not immediately.
• Pipeline: Plans to initiate pivotal clinical trials for Cosmetic Tissue Augmentation (CTA) and a pilot trial for INCERT (adhesion prevention) in Q2 2004.

Outlook: Management expects R&D and SG&A expenses to increase in 2004 due to new clinical trials and marketing efforts for ORTHOVISC. Gross margins are expected to improve further with increased volume.

Risks & Contingencies:

• Customer Dependence: Heavy reliance on Bausch & Lomb (51% of revenue) and Ortho Biotech for future U.S. sales.
• Regulatory Risk: Future products (CTA, INCERT) require FDA Class III approval (PMA), which is costly and uncertain.
• Intellectual Property: Risks regarding patent interference proceedings for INCERT and potential infringement claims.
• Restatement History: The company previously restated 2002 results due to premature revenue recognition of HYVISC sales; this matter was settled with the SEC in Jan 2003 with no monetary sanctions.

Investor Verification Checklist

• Revenue Recognition Policy: Verify the ratable recognition schedule for the $22 million received from Ortho Biotech ($2M upfront + $20M milestone) to ensure it is not booked as immediate income.
• Bausch & Lomb Contract Terms: Review the volume-based pricing adjustments in the Bausch & Lomb agreement, which can cause retroactive revenue reductions.
• ORTHOVISC Sales Performance: Monitor Q1 and Q2 2004 sales data to validate the commercial success of the U.S. launch under the Ortho Biotech partnership.
• Cash Burn Rate: Assess if the $14.6 million cash balance (plus the $20M milestone) is sufficient to fund the planned 2004 clinical trials and manufacturing expansion without dilutive financing.
• Patent Status: Confirm the status of the patent interference proceeding regarding INCERT to evaluate the viability of the adhesion prevention pipeline.